Literature DB >> 16938755

Morphine-related apnoea in CPAP-treated preterm neonates.

Jan Enders1, Corinna Gebauer, Ferdinand Pulzer, Eva Robel-Tillig, Matthias Knüpfer.   

Abstract

BACKGROUND: Morphine can be used to treat pain in preterm neonates with CPAP because of its analgetic potency; however, it is known to induce apnoea. AIM: To evaluate this risk of apnoea.
METHODS: We retrospectively analysed 91 preterm neonates with CPAP who received morphine intravenously. The incidence of apnoea 4 h before and after morphine administration was compared. The data were analysed for three dosage groups (<0.01, 0.01-0.03 and 0.03 mg/kg) and according to the incidence of apnoea before morphine application.
RESULTS: In the whole group (gestational age 29.1+/-2.9 wk, morphine dosage 0.017+/-0.01 mg/kg) we did not find differences in apnoea before and after morphine (0.9+/-1.8 vs 1.1+/-1.8 apnoea). The only significant increase in apnoea was seen in the subgroup of patients receiving > 0.03 mg/kg (0.3+/-0.67 vs 1.5+/-2.5 apnoea). Interestingly, we found a significantly delayed increase in apnoea in the fourth hour.
CONCLUSION: Morphine in preterm infants with CPAP is not widely accepted practice until further randomized studies evaluate efficacy and safety. Morphine in a low dosage (<or=0.03 mg/kg) did not significantly increase the apnoea rate in CPAP-treated preterm infants. For clinical work, it is very important to note that morphine-related apnoea may appear with a delay of approximately 4 h.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16938755     DOI: 10.1080/08035250600577871

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  1 in total

Review 1.  Pharmacoepidemiological safety studies in children: a systematic review.

Authors:  Osemeke U Osokogu; Julijana Dukanovic; Carmen Ferrajolo; Caitlin Dodd; Alexandra C Pacurariu; Wichor M Bramer; Geert 'tJong; Daniel Weibel; Miriam C J M Sturkenboom; Florentia Kaguelidou
Journal:  Pharmacoepidemiol Drug Saf       Date:  2016-06-03       Impact factor: 2.890

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.